Will Getting A Testosterone Shot Make You Lose Sleep
The Short-Term Effects of High-Dose Testosterone on Sleep, Breathing, and Function in Older Men
Peter Y. Liu, 1Department of Andrology, ANZAC Research Institute and Concord Hospital (P.Y.L., S.M.W., M.J., D.J.H.), Sydney, 2139 Australia Search for other works by this author on: 2Woolcock Institute of Medical Research and Royal Prince Alfred Hospital (B.Y., D.G.J., R.R.G.), University of Sydney, Sydney, 2139 Australia Search for other works by this author on: 1Department of Andrology, ANZAC Research Institute and Concord Hospital (P.Y.L., S.M.W., M.J., D.J.H.), Sydney, 2139 Australia Search for other works by this author on: 1Department of Andrology, ANZAC Research Institute and Concord Hospital (P.Y.L., S.M.W., M.J., D.J.H.), Sydney, 2139 Australia Search for other works by this author on: 2Woolcock Institute of Medical Research and Royal Prince Alfred Hospital (B.Y., D.G.J., R.R.G.), University of Sydney, Sydney, 2139 Australia Search for other works by this author on: 2Woolcock Institute of Medical Research and Royal Prince Alfred Hospital (B.Y., D.G.J., R.R.G.), University of Sydney, Sydney, 2139 Australia Search for other works by this author on: 1Department of Andrology, ANZAC Research Institute and Concord Hospital (P.Y.L., S.M.W., M.J., D.J.H.), Sydney, 2139 Australia *Address all correspondence and requests for reprints to: Prof. David J. Handelsman, ANZAC Research Institute, Sydney NSW 2139 Australia. Search for other works by this author on:
Received:
12 February 2003
Published:
01 August 2003
Androgen therapy may precipitate obstructive sleep apnea in men. Despite increasing androgen use in older men, few studies have examined sleep and breathing. Randomized, double-blind, placebo-controlled studies examining effects of testosterone simultaneously on sleep, breathing, and function in older men are not available. Seventeen community-dwelling healthy men over the age of 60 yr were randomized to receive three injections of im testosterone esters at weekly intervals (500 mg, 250 mg, and 250 mg) or matching oil-based placebo and then crossed over to the other treatment after 8 wk of washout. Polysomnography, anthropometry, and physical, mental, and metabolic function were assessed at baseline and after each treatment period. Testosterone treatment reduced total time slept (∼1 h), increased the duration of hypoxemia (∼5 min/night), and disrupted breathing during sleep (total and non-rapid eye movement respiratory disturbance indices both increased by approximately seven events per hour) (all P < 0.05). Despite expected effects on body composition (increase in total and lean mass, reduction in fat mass, P < 0.05, bioimpedance method), upper airway dimensions did not change (acoustic reflectometry). Driving ability (computer simulation), physical activity (accelerometry, Physical Activity Scale in the Elderly), quality of life (SF36, Functional Outcomes of Sleep Questionnaire), mood (Profile of Mood States Questionnaire), sleepiness (Epworth, Stanford scales), and insulin resistance (homeostasis model) also were not changed by treatment. Short-term administration of high-dose testosterone shortens sleep and worsens sleep apnea in older men but did not alter physical, mental, or metabolic function. These changes did not appear to be due to upper airway narrowing. Further study of longer-term lower-dose androgen therapy on sleep and breathing is needed to evaluate its safety in older men.
OBSTRUCTIVE SLEEP APNEA (OSA) can cause death as well as cardiovascular, metabolic, and neuropsychological morbidity. Its prevalence increases with age, has a male preponderance with up to 25% of working age men having disturbed breathing during sleep (1), and up to 80% of cases of OSA remain undiagnosed. The pathophysiological basis of OSA is periodic airway occlusion resulting in sleep and blood gas disturbance that leads to cardiovascular disease, hypertension, arrhythmia, increased risk of traffic accidents, disturbed psychosocial performance, and metabolic and neuroendocrine dysfunction (2).
Androgen treatment has long been believed to precipitate OSA in some men (3). However, few studies have systematically examined the effect of androgen treatment on breathing or sleep (4–9). There are no randomized placebo-controlled studies that have examined the effect of androgen treatment on both sleep and breathing, although one has reported no reduction in sleep (7) and the other no worsening of breathing (9). Furthermore, no study has shown that androgen treatment shortens sleep or impairs physical or mental function. Although inconsistent effects on sleep architecture are reported, the paucity of well-designed studies using gold standard endpoints (such as overnight polysomnography) means that the safety of androgen therapy during sleep remains uncertain.
Concurrently there is increased interest in the use of androgen supplementation in older men to improve body composition, muscle and bone strength, and physical functioning (10–19). These studies have consistently recruited men over 60 yr of age with baseline plasma testosterone concentrations ≤430 ng/dl (15 nmol/liter, which includes the lower end of the young eugonadal male reference range) because men with lower baseline testosterone concentrations are more likely to be androgen responsive (14, 20). Most of these studies have treated men for less than 6 months, and there are no long-term studies of high-dose testosterone treatment. Because of the paucity of data, this study was designed to examine the safety of short-term, high-dose testosterone treatment on sleep, breathing, and mental and physical function in older men, and, therefore, the duration of exposure was minimized to reduce the risk to participants.
Subjects and Methods
Study design
The study was designed as a randomized sequence, double blind, placebo-controlled cross-over study of 17 eligible and evaluable men (Fig. 1). Subjects were randomly assigned to receive either testosterone esters (250 mg/ml, Sustanon 250, Organon Australia, Sydney, Australia) or arachis oil volume-matched placebo (Department of Pharmacy, Concord Hospital) during the first period before crossing over to the other treatment. Each treatment period consisted of three im injections spaced 1 wk apart. The first injection was 2 ml (equal to 500 mg testosterone esters in the treatment group), and the subsequent two injections were 1 ml (250 mg testosterone ester) each. There was a washout period of 8 wk between the two treatment periods, which would allow complete clearance of administered testosterone. All injections were administered by staff of the Department of Andrology. Subjects were advised to report any injection-related (stinging, bruising, or pain) adverse event. Adverse events or intercurrent illness and their likely relationship with drug administration were recorded prospectively. Anthropometry, sleep studies, driving, and physical and mental function were assessed at baseline and after each study period (2–4 d after the last im injection to capture the maximal circulating testosterone concentrations). More easily obtained variables [blood, SF36, International Prostate Symptom Score (IPSS), Physical Activity Scale in the Elderly (PASE) ] in subjects were obtained at 1- to 2-wk intervals (Fig. 1). All study procedures were approved by the CSAHS Ethics Committee within National Health and Medical Research Council (Australia) guidelines. The trial was conducted under the TGA (Australia) clinical trial notification scheme.
Fig. 1.
Study design. For further details see text.
Fig. 1.
Study design. For further details see text.
Subjects and treatment
Healthy, ambulatory and community-dwelling men older than 60 yr of age were recruited if they had a plasma testosterone ≤430 ng/dl (15 nmol/liter) on two separate occasions. They were excluded because of: 1) presence of severe snoring or sleepiness requiring investigation and treatment; 2) contraindication to testosterone use including breast cancer, prostate cancer, or disease requiring further treatment; 3) unstable, uncontrolled or severe chronic medical disease; 4) medical conditions that might interfere with evaluation of sleep or physical activity (including physical incapacity or dementia); or 5) medication use known to interact with sex steroid action or alter sleep
Study procedures
Volunteers were recruited through public advertisement. Respondents were provided with an explanation of the study and a written information sheet and were required to sign a consent form. Standardized medical history, physical examination, and blood samples were obtained at entry. Fasting blood samples were taken between 0830 and 1030 h before injection of study drug, and participants were asked not to vary their diet or exercise patterns. Eligible subjects who satisfied all entry criteria were randomly assigned a study number that corresponded with individually numbered drug supplies. The Department of Pharmacy (Concord Hospital) held the randomization list (obtained by random-number generator) and dispensed all study medications. At the end of the study, subjects nominated the period during which active treatment was administered to assess adequacy of blinding.
Assays and insulin sensitivity
Serum samples were stored frozen for measurement, within a single assay, using commercially available DELFIA immunoassays (Perkin-Elmer Life Sciences, Rowville, Australia) for LH, FSH, total testosterone, SHBG, insulin, and prostate-specific antigen (PSA). Leptin was measured by double-antibody RIA (Linco Research Inc., St Louis, Mo) assay. Blood glucose was determined by the hexokinase method (Hitachi 917 autoanalyzer, Roche Diagnostics, Castle Hill, Australia) from blood collected in sodium fluoride (Vacutainer; Becton Dickinson, Rutherford, NJ) during the previous 2 h. Within assay coefficients of variation were less than 10% for all assays, and detection limits for gonadotropin assays were 0.1–0.2 IU/liter. Insulin resistance and production were calculated according to the homeostasis model (21).
Anthropometry and upper airway caliber
Anthropometry and upper airway caliber were assessed in all subjects on three occasions (baseline, end of phase 1, and end of phase 2) by a single observer. Anthropometric (22) and bioimpedance measurements were taken while fasting before the first and last injection of each study phase immediately after micturition as previously reported (19). Lean mass was estimated from bioimpedance (SEAC model BIM 3.0 bioimpedance meter, Inderlec, Brisbane, Australia) according to Lukaski and Bolunchuk's formula and fat mass, obtained by subtraction from body weight (23).
Upper airway caliber was assessed by acoustic reflectometry (24) (Eccovision pharyngometer; E. Benson Hood Laboratories, Pembroke, MA). Airway dimension at the pharynx, glottis, and oropharyngeal junction were measured with the subject awake and in four positions (supine, erect, and in the left and right lateral) while breathing quietly at tidal volume.
Polysomnography
Sleep and breathing were assessed by full overnight polysomnography (at RPAH Sleep Disorders Centre) after one night of laboratory acclimatization in all subjects on three occasions (baseline, end of phase 1, and end of phase 2) and as previously described (25). Chest wall and abdominal motion were recorded using Respitrace (Ambulatory Monitoring Inc., Ardsley, NY), airflow was measured by nasal pressure (pressure transducer; Validyne, Northridge, CA) and arterial oxyhemoglobin saturation with a Biox 3700e (Ohmeda, Louisville, CO). Subjects were asked to maintain their usual sleeping pattern (and not to nap during the day) before sleep studies. Data were recorded continuously on a computerized polygraph (Compumedics E series, Melbourne, Australia) and scored by a single blinded technologist using American Academy of Sleep Medicine consensus methods (26) to calculate respiratory disturbance indices and sleep stage. In brief, apneas occurred when airflow ceased, whereas hypopneas occurred when airflow or thoracoabdominal movement fell by at least 50%. Apneas and hypopneas had to be of at least 10 sec duration and were classified as obstructive if there was continued diaphragm electromyographic activity or thoracoabdominal wall movement otherwise they were central. The total respiratory disturbance index (RDI) was calculated as the number of apneas and hypopneas that occurred per hour of sleep and were subdivided into rapid eye movement (REM) RDI and non-REM (NREM) RDI according to whether events occurred in REM or NREM sleep, respectively. Sleep stages [sleep stage 1 (S1), 2 (S2), 3 (S3), 4 (S4), NREM, and REM sleep] were defined by standard electroencephalographic criteria (26). Sleep efficiency (the proportion of time slept while in bed), sleep-related hypoxemia (oxygen saturation <90%, during sleep), and nadir oxygen saturation during sleep were also determined.
Driving performance task
Driving ability was assessed by computer simulation (27) in a darkened room (AusEd, Diagnose IT, Sydney, Australia) at baseline and after each study phase. In brief, all subjects performed a 30-min driving performance task after a 20-min practice session in a darkened room at 2000 h in the evening. The object of the test was to steer an image of a car hood along a predefined monotonous, night-driving course as accurately as possible within a velocity range indicated on a screen speedometer. To test vigilance and reaction time, subjects had to brake when a visual image of a truck randomly appeared. The driving simulator recorded tracking error (ability to steer accurately), velocity deviation (time outside mandatory speed range), reaction time (average time to respond to visual stimulus), and number of crashes.
Physical activity and questionnaires
Physical activity was determined objectively by accelerometry (TriTrac R3D ergometer; ZMD Reining Inc., Madison, WI) (28) using the manufacturer's proprietary software (Tritrac R3D software, version 6.05) and by PASE questionnaire (29).
General [SF36 (30)] and sleep-specific [Functional Outcomes of Sleep Questionnaire (FOSQ) (31)[ quality of life as well as sleepiness [Stanford and Epworth sleepiness scale (32)] were assessed before and after treatment in each phase of the study. Mood was assessed by the Profile of Mood States Questionnaire (POMS) (33) and lower urinary tract symptoms associated with prostate growth were assessed by the IPSS (34).
Statistical analysis
The randomization code was not broken until all data were collected and the resulting database cleaned and locked. Standard techniques to transform nonnormal data (Shaprio-Wilk test) and examine for carryover and period effects were used (35). Response to testosterone treatment was analyzed by paired t test (35). For data with repeated measures, treatment and placebo data were pooled separately by averaging and then analyzed analogously. These results were confirmed by a two-way ANOVA model with main effects for order (placebo or testosterone treatment first) and time, with repeated measures on time. In this model, treatment effect was determined by the interaction between order and time and period effects by the time variable. The results of this method are not presented unless they differ significantly from the previous. Pearson's correlations were determined to assess linear associations between baseline hormonal data and change in breathing or sleep. All data are expressed as mean ± sem. Data were considered significantly different at P ≤ 0.05 (two sided). Analyses were performed using SPSS 10.0 (SPSS Inc., Chicago, IL).
Results
Characteristics and disposition of participants
Seventeen eligible men aged 67.5 ± 0.8 (sem) yr were recruited with nine receiving testosterone first. One subject was discontinued at the end of the second period (while on placebo) because of recurrence of long-standing cervical neck pain. There were no other serious adverse events, and no adverse event was considered to be drug related except for two men who had transient nipple tenderness while receiving testosterone and injection-related pain that occurred in three of 102 injections.
Sixteen evaluable men completed the study. There were no missing appointments and minimal missing data (<1%) arising from equipment failure. Period and carryover effects were not detected. Subjects were unable to correctly predict their treatment assignments at the end of the study (only 65% guessed correctly, P = 0.33) suggesting adequate blinding.
Hormonal and anthropometric effects
Testosterone treatment significantly suppressed LH and FSH to the detection limit of the assay and markedly increased serum total testosterone and estradiol by 2- to 3-fold (Fig. 2). Leptin fell, but there were no significant changes in SHBG, insulin, glucose, or PSA (not all data shown). IPSS (lower urinary tract symptoms) was not changed by treatment (not shown).
Fig. 2.
Plot of mean and se of mean for blood parameters. The left plot (light gray) shows baseline, and the right plot shows the change from baseline in the pooled testosterone (dark gray) and pooled placebo (white) groups. Significant differences among groups are indicated by the asterisk. Note significant change in leptin, FSH, LH, estradiol (E2), and testosterone (T). In some instances the scale of the left and right plots differ. To convert values for estradiol from pmol/liter (pm) to pg/ml, divide by 3.671. To convert values for testosterone from nmol/liter (nm) to ng/dl, divide by 0.03467. For further details, see text.
Fig. 2.
Plot of mean and se of mean for blood parameters. The left plot (light gray) shows baseline, and the right plot shows the change from baseline in the pooled testosterone (dark gray) and pooled placebo (white) groups. Significant differences among groups are indicated by the asterisk. Note significant change in leptin, FSH, LH, estradiol (E2), and testosterone (T). In some instances the scale of the left and right plots differ. To convert values for estradiol from pmol/liter (pm) to pg/ml, divide by 3.671. To convert values for testosterone from nmol/liter (nm) to ng/dl, divide by 0.03467. For further details, see text.
During treatment, testosterone significantly increased total weight (∼2 kg) and lean mass (∼3 kg) and reduced fat mass (∼1 kg) (Fig. 3). There was no significant change in either abdominal or neck circumferences or in upper airway caliber (data not shown).
Fig. 3.
Plot of mean and se of mean for anthropometric parameters. The left plot (light gray) shows baseline, and the right plot shows the change from baseline in the pooled testosterone (dark gray) and pooled placebo (white) groups. Significant differences between groups are indicated by the asterisk. Note significant change in total, lean and fat mass, and BMI. In some instances the scale of the left and right plots differ. For further details, see text.
Fig. 3.
Plot of mean and se of mean for anthropometric parameters. The left plot (light gray) shows baseline, and the right plot shows the change from baseline in the pooled testosterone (dark gray) and pooled placebo (white) groups. Significant differences between groups are indicated by the asterisk. Note significant change in total, lean and fat mass, and BMI. In some instances the scale of the left and right plots differ. For further details, see text.
Polysomnography
Total time slept was shorter on testosterone treatment (∼1 h) with a reduction in both NREM (particularly stage 2) and REM sleep as well as sleep efficiency (Fig. 4). The proportion of total time slept in NREM and REM sleep did not change (data not shown). The total RDI (∼7 events/h) was increased by testosterone, and this was due predominantly to events occurring in NREM sleep (∼7 events/h, Fig. 5). Absolute (∼5 min) and relative (as a proportion of total time slept, by ∼2%) hypoxemia was prolonged, but nadir oxygen saturation was not altered by testosterone treatment (Fig. 5).
Fig. 4.
Plot of mean and se of mean for polysomnographic sleep parameters. The left plot (light gray) shows baseline, and the right plot shows the change from baseline in the pooled testosterone (dark gray) and pooled placebo (white) groups. Significant differences among groups are indicated by the asterisk. Note significant decrease in total, REM, and non-REM time slept. Time in stage 2 sleep is also significantly reduced. In some instances the scale of the left and right plots differ. Sleep stages are abbreviated as sleep stage 1 (S1), 2 (S2), 3 (S3), 4 (S4), REM, and NREM sleep. For further details, see text.
Fig. 4.
Plot of mean and se of mean for polysomnographic sleep parameters. The left plot (light gray) shows baseline, and the right plot shows the change from baseline in the pooled testosterone (dark gray) and pooled placebo (white) groups. Significant differences among groups are indicated by the asterisk. Note significant decrease in total, REM, and non-REM time slept. Time in stage 2 sleep is also significantly reduced. In some instances the scale of the left and right plots differ. Sleep stages are abbreviated as sleep stage 1 (S1), 2 (S2), 3 (S3), 4 (S4), REM, and NREM sleep. For further details, see text.
Fig. 5.
Plot of mean and se of mean for polysomnographic breathing parameters. The left plot (light gray) shows baseline, and the right plot shows the change from baseline in the pooled testosterone (dark gray) and pooled placebo (white) groups. Significant differences among groups are indicated by the asterisk. Note significant change in total and NREM RDI, sleep efficiency, and absolute and relative duration of hypoxemia. In some instances the scale of the left and right plots differ. For further details, see text.
Fig. 5.
Plot of mean and se of mean for polysomnographic breathing parameters. The left plot (light gray) shows baseline, and the right plot shows the change from baseline in the pooled testosterone (dark gray) and pooled placebo (white) groups. Significant differences among groups are indicated by the asterisk. Note significant change in total and NREM RDI, sleep efficiency, and absolute and relative duration of hypoxemia. In some instances the scale of the left and right plots differ. For further details, see text.
To determine whether any baseline hormonal or sleep variables were predictive of worse sleep response to testosterone treatment, Pearson's correlations were determined. No significant associations were found (data not shown). In particular, baseline total testosterone was not significantly correlated with change in total RDI, NREM RDI or REM RDI, or time slept in total or during NREM or REM sleep (all P > 0.05). Furthermore, baseline total RDI was not significantly correlated with change in total RDI, NREM RDI or REM RDI, or time slept in total or during NREM or REM sleep (all P > 0.05).
Physical and mental function and quality of life
Driving ability (ability to steer and maintain constant speed, crashes, and divided attention) was not altered by testosterone treatment. Physical activity (accelerometry and PASE), mood (POMS), sleepiness (Epworth and Stanford), and quality of life (FOSQ and SF-36) were not altered by testosterone treatment. Metabolic function (homeostasis model assessment-derived insulin resistance and production) was unchanged. (Fig. 6, not all data shown).
Fig. 6.
Plot of mean and se of mean for physical and mental function and quality of life. The left plot (light gray) shows baseline, and the right plot shows the change from baseline in the pooled testosterone (dark gray) and pooled placebo (white) groups. Significant differences among groups are indicated by the asterisk. No significant changes were detected in homeostasis model assessment (HOMA) determined insulin resistance or insulin production, FOSQ, total SF36 score, Epworth or Stanford sleepiness scales, PASE, the vigor component of the POMS, or steering or speed deviation of the driving performance task. In some instances the scale of the left and right plots differ. For further details, see text.
Fig. 6.
Plot of mean and se of mean for physical and mental function and quality of life. The left plot (light gray) shows baseline, and the right plot shows the change from baseline in the pooled testosterone (dark gray) and pooled placebo (white) groups. Significant differences among groups are indicated by the asterisk. No significant changes were detected in homeostasis model assessment (HOMA) determined insulin resistance or insulin production, FOSQ, total SF36 score, Epworth or Stanford sleepiness scales, PASE, the vigor component of the POMS, or steering or speed deviation of the driving performance task. In some instances the scale of the left and right plots differ. For further details, see text.
Discussion
This is the first randomized placebo-controlled study to show that high-dose testosterone therapy can disrupt sleep and breathing, increase sleep-related hypoxemia, and potentially precipitate obstructive sleep apnea. It resolves the uncertainty arising from the original case report (3, 36) and subsequent contradictory and inconclusive randomized studies (6, 9). Furthermore, this is the first study to show that high-dose testosterone therapy can shorten time slept, although inconsistent effects on sleep architecture have been previously described (7). Sleep loss of the magnitude described in this study can impair cognitive and physical performance in younger individuals (37), and the combination of reduction in sleep time and obstructive sleep apnea is particularly harmful because sleep deprivation can worsen disordered breathing (38). In addition, the absolute and relative (to the proportion of total time slept) duration of hypoxemia increased, although there was no reduction in nadir oxygen saturation. This study, therefore, underlines the safety concerns of testosterone treatment in older men.
Despite worsened breathing, lengthened hypoxemia, and shortened sleep, no alteration in physical or mental function (driving ability, self-reported and objectively recorded physical activity, mood, sleepiness, or quality of life) or metabolic function (insulin resistance) was detected, although changes may have occurred with prolonged therapy. Insulin resistance is associated with OSA (39–41) independent of visceral obesity (42, 43), and it may be that there was no net effect because disordered breathing worsens and reduced adiposity improves insulin action. It is possible that the short duration of high-dose androgen therapy chosen (to minimize any potential adverse effects) was not long enough to cause detectable physical, mental or metabolic changes, particularly because the increase in sleep-disordered breathing and duration of hypoxemia were both moderate in magnitude. However, prolonged therapy, which would be required to maintain body compositional and other physical performance improvements in older men, may have resulted in chronic low-level hypoxemia leading to impaired cardiovascular, neurological, and physical function. In addition, sleep deprivation, particularly when sustained, will impair physical and mental function in older individuals, although the magnitude of the effect is reduced, compared with the young (44).
Alternatively, napping during the day (against specific instructions) may have compensated for the decrease in sleep at night, but there is no evidence for this. It is also possible that the methods used were not sensitive enough to detect subtle changes in physical, mental, or metabolic function. However, our methods to measure driving ability, physical activity, and insulin resistance are validated (21, 27–29, 45) and widely used.
Testosterone may worsen breathing by a number of mechanisms because upper airway patency is determined by many structural and neuromuscular factors that control pharyngeal airway size and collapsibility. Obesity, as reflected by body mass index (BMI) and neck circumference (46), is associated with OSA. However, this association is explained by upper airway narrowing (24) probably via pharyngeal fat deposition (47, 48). Although testosterone treatment resulted in an increase in BMI, adiposity (and presumably pharyngeal fat) was reduced (as measured by bioimpedance), consistent with the observed reduction in serum leptin concentration. It is also possible that these rapid change in body composition reflect changes in hydration because of high doses of testosterone used in a short period of time and that the disturbed breathing arose from upper airway edema. However, fluid shifts do not occur in young men treated with comparable doses of testosterone esters (49). Furthermore, direct measurement of upper airway caliber (by acoustic reflectometry) at the narrowest (the oropharyngeal junction) and widest (maximal pharyngeal area) locations, as well as neck or abdominal circumferences, did not change with treatment. Because these measurements were performed with the subjects awake, we cannot exclude the possibility that upper airway narrowing may have occurred specifically during sleep. Although a direct anabolic effect on upper airway soft tissue growth could result in a physical reduction in upper airway dimension and this is thought to be how androgens induce OSA in women (50–52), the duration of therapy in this study was too short for this to have occurred.
Testosterone may worsen breathing by neuromuscular mechanisms. Testosterone treatment increases upper airway collapsibility (53), ventilation (54), and hypoxic (54) and hypercapnic ventilatory responses (55), leading to a reduced apneic threshold. These effects on breathing may occur particularly during NREM sleep (55), which is consistent with our findings.
Although androgen deficiency, particularly in older men, is associated with insomnia and other sleep disturbances, a marked reduction in time slept with testosterone administration was actually observed. It may be that high and low circulating testosterone concentrations are both associated with sleep disturbances. Testosterone may directly alter sleep through central nervous system effects including altered serotingergic neurotransmission (56). Testosterone increases nocturnal metabolic rate (54), potentially impairing sleep quality (57).
An important caveat of this study was that, as expected, treatment resulted in high supraphysiological serum testosterone concentrations and sleep and function were measured at the time of expected peak concentrations. Such high doses have been used therapeutically in pilot studies in older men (58), but there are no long-term studies and on the basis of our findings, long-term, high-dose androgen use in older men cannot be recommended, although the safety of long-term, low-dose androgen use remains to be clarified. Hence, our findings are applicable mostly to short-term, high-dose testosterone ester administration and may not be applicable to lower-dose physiological replacement, particularly with preparations (such as transdermal or subdermal testosterone therapy), which do not result in supraphysiological peak serum concentrations (9). Nevertheless, im testosterone ester administration is a widely used and studied form of therapy among older men (10–13, 17).
We also observed the phenomenon of "regression to the mean" (59) in baseline testosterone concentrations, whereby despite screening requirements of less than 430 ng/dl (15 nmol/liter), the subsequent pretreatment baseline testosterone concentration was modestly higher (16, 19). Hence, many of our men had a baseline testosterone within the young normal range. We also showed that a lower baseline testosterone or a higher baseline total respiratory disturbance index was not linearly associated with greater worsening of any breathing or sleep parameter. This suggests that excluding subjects for androgen therapy on the basis of preexisting OSA may not be sufficient, and conversely, hypogonadal men with coexistent OSA should not necessarily be denied androgen therapy. Nevertheless, monitoring of sleep and breathing would be prudent in hypogonadal men with symptoms (e.g. snoring, daytime sleepiness, morning headache) of or risk factors (e.g. obesity) for OSA commencing androgen replacement, particularly replacement with im testosterone esters (3, 4–7, 53). This is particularly prudent because this study specifically included men without symptoms of severe OSA and may, therefore, have excluded men who may have been more adversely affected by androgen therapy. However, at baseline many of the men had disturbed breathing, defined polysomnographically, consistent with men of this age. The clinical significance of these laboratory-based measurements is uncertain in the absence of symptoms of OSA. However, no man was diagnosed with severe OSA requiring treatment, although four men were offered further evaluation and two men subsequently received a trial of continuous positive airway pressure.
Short-term prostate safety was suggested by the lack of change in PSA and IPSS, consistent with other longer-term but lower-dose studies (14, 16, 19). Uniquely, this study shows that high-dose treatment, sufficient to increase serum testosterone and estradiol by 2- to 3-fold will not acutely alter PSA or induce lower urinary tract symptoms in older men if ultrashort duration therapy is used.
Nevertheless, this study raises concerns about the safety of long-term androgen therapy in older men with partial age-related androgen deficiency. Consideration for breathing and sleep safety must now be placed alongside concerns regarding prostate disease (60) and polycythemia (61). Given the recently recognized adverse effects of hormone replacement therapy in older women (62), this is a salutatory reminder that high-quality studies examining both efficacy and safety are required before widespread adoption of androgen replacement in older men can be recommended.
Acknowledgements
We are indebted to the staff of the Departments of Andrology and Pharmacy (Concord Hospital) and Centre for Respiratory Failure and Sleep Disorders (Royal Prince Alfred Hospital) for their valued help. Organon Australia donated testosterone ampoules.
This work was supported by National Health and Medical Research Council of Australia Grants 142613 and 262025. There are no financial disclosures by any of the authors. This study was presented in part during the Clinical Trials Symposium of the 84th Annual Meeting of The Endocrine Society, San Francisco, California, June 20–23, 2002.
Abbreviations:
-
BMI,
-
FOSQ,
Functional Outcomes of Sleep Questionnaire;
-
IPSS,
International Prostate Symptom Score;
-
NREM,
-
OSA,
-
PASE,
Physical Activity Scale in the Elderly;
-
POMS,
Profile of Mood States Questionnaire;
-
PSA,
prostate-specific antigen;
-
RDI,
respiratory disturbance index;
-
REM,
1
Young
T
, Palta M Dempsey J Skatrud J Weber S Badr S
1993
The occurrence of sleep-disordered breathing among middle-aged adults.
N Engl J Med
328
:
1230
–
1235
2
Grunstein
RR
, Hedner J Grote L
2001
Treatment options for sleep apnoea.
Drugs
61
:
237
–
2351
3
Sandblom
RE
, Matsumoto AM Scoene RB Lee KA Giblin EC Bremner WJ Pierson DJ
1983
Obstructive sleep apnea induced by testosterone administration.
N Engl J Med
308
:
508
–
510
4
Millman
RP
, Kimmel PL Shore ET Wasserstein AG
1985
Sleep apnea in hemodialysis patients: the lack of testosterone effect on its pathogenesis.
Nephron
40
:
407
–
410
5
Matsumoto
A
, Sandblom RE Schoene RB Lee KA Giblin EC Pierson DJ Bremner WJ
1985
Testosterone replacement in hypogonadal men: effects on obstructive sleep apnea, respiratory drives and sleep
.
Clin Endocrinol
22
:
713
–
721
6
Schneider
BK
, Pickett CK Zwillich CW Weil JV McDermott MT Santen RJ Varano LA White DP
1986
Influence of testosterone on breathing during sleep.
J Appl Physiol
61
:
618
–
623
7
Leibenluft
E
, Schmidt PJ Turner EH Danaceau MA Ashman SB Wehr TA Rubinow DR
1997
Effects of leuprolide-induced hypogonadism and testosterone replacement on sleep, melatonin, and prolactin secretion in men.
J Clin Endocrinol Metab
82
:
3203
–
3207
8
Luboshitzky
R
, Lavi S Lavie P
1999
The association between melatonin and sleep stages in normal adults and hypogonadal men.
Sleep
22
:
867
–
874
9
Snyder
PJ
, Peachey H Hannoush P Berlin JA Loh L Holmes JH Dlewati A Staley J Santanna J Kapoor SC Attie MF Haddad JG Strom BL
1999
Effect of testosterone treatment on bone mineral density in men over 65 years of age.
J Clin Endocrinal Metab
84
:
1966
–
1972
10
Tenover
JS
1992
Effects of testosterone supplementation in the aging male.
J Clin Endocrinal Metab
75
:
1092
–
1098
11
Morley
JE
, Perry HM Kaiser FE Kraengle D Jensen J Houston K Mattammal M Perry HM
1993
Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study.
J Am Geriatr Soc
41
:
149
–
152
12
Sih
R
, Morley JE Kaiser FE Perry HM Patrick P Ross C
1997
Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial.
J Clin Endocrinal Metab
82
:
1661
–
1667
13
Clague
JE
, Wu FCW Horan MA
1999
Difficulties in measuring the effect of testosterone replacement therapy on muscle function in older men.
Int Androl
22
:
261
–
265
14
Snyder
PJ
, Peachey H Hannoush P Berlin JA Loh L Lenrow DA Holmes JH Dlewati A Santanna J Rosen CJ Strom BL
1999
Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age.
J Clin Endocrinal Metab
84
:
2647
–
2653
15
Kenny
AM
, Prestwood KM Gruman CA Marcello KM Raisz LG
2001
Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels
.
J Gerontol Ser A Biol Sci Med Sci
56
:
M266
–
M272
16
Ly
LP
, Jimenez M Zhuang TN Celermajer DS Conway AJ Handelsman DJ
2001
A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency.
J Clin Endocrinol Metab
86
:
4078
–
4088
17
Ferrando
AA
, Sheffield-Moore M Yeckel CW Gilkison C Jiang J Achacosa A Lieberman SA Tipton K Wolfe RR Urban RJ
2002
Testosterone administration to older men improves muscle function: molecular and physiological mechanisms
.
Am J Physiol Endocrinol Metab
282
:
E601
–
E607
18
Lambert
CP
, Sullivan DH Freeling SA Lindquist DM Evans WJ
2002
Effects of testosterone replacement and/or resistance exercise on the composition of megestrol acetate stimulated weight gain in elderly men: a randomized controlled trial.
J Clin Endocrinol Metab
87
:
2100
–
2106
19
Liu
PY
, Wishart SM Handelsman DJ
2002
A double-blind, placebo- controlled, randomized clinical trial of recombinant human chorionic gonadotropin on muscle strength and physical function and activity in older men with partial age-related androgen deficiency.
J Clin Endocrinol Metab
87
:
3125
–
3135
20
Marin
P
, Holmang S Jonsson L Sjostrom L Kvist H Holm G Lindstedt G Bjorntorp P
1992
The effects of testosterone treatment on body composition and metabolism in middle-aged obese men.
Int J Obes Relat Metab Disord
16
:
991
–
997
21
Matthews
DR
, Hosker JP Rudenski AS Naylor BA Treacher DF Turner RC
1985
Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.
Diabetologia
28
:
412
–
419
22
Lohman
TG
, Roche AF Martorell R
1988
Anthropometric standardization reference manual
.
Champaign, IL
:
Human Kinetics Books
23
Lukaski
HC
, Bolonchuk WW
1987
Theory and validation of the tetrapolar bioelectrical impedance method to assess human body composition
.
In: Ellis KJ, Yasumura S, Morgan WD, eds. Proceedings of the International Symposium on In Vivo Body Composition Studies. London: Institute of Medical Physics;
410
–
414
24
Bradley
TD
, Brown IG Grossman RF Zamel N Martinez D Phillipson EA Hoffstein V
1986
Pharyngeal size in snorers, nonsnorers, and patients with obstructive sleep apnea.
N Engl J Med
315
:
1327
–
1331
25
Stewart
DA
, Grunstein RR Berthon-Jones M Handelsman DJ Sullivan CE
1992
Androgen blockade does not affect sleep-disordered breathing or chemosensitivity in men with obstructive sleep apnea.
Am Rev Respir Dis
146
:
1389
–
1393
26
Anonymous
1999
Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force.
Sleep
22
:
667
–
689
27
Land
M
, Horwood J
1995
Which parts of the road guide steering?
Nature
377
:
339
–
340
28
Nichols
JF
, Morgan CG Sarkin JA Sallis JF Calfas KJ
1999
Validity, reliability, and calibration of the Tritrac accelerometer as a measure of physical activity.
Med Sci Sports Exerc
31
:
908
–
912
29
Schuit
AJ
, Schouten EG Westerterp KR Saris WH
1997
Validity of the Physical Activity Scale for the Elderly (PASE): according to energy expenditure assessed by the doubly labeled water method.
J Clin Epidemiol
50
:
541
–
546
30
McCallum
J
1995
The SF-36 in an Australian sample: validating a new, generic health status measure.
Aust J Public Health
19
:
160
–
166
31
Weaver
TE
, Laizner AM Evans LK Maislin G Chugh DK Lyon K Smith PL Schwartz AR Redline S Pack AI Dinges DF
1997
An instrument to measure functional status outcomes for disorders of excessive sleepiness.
Sleep
20
:
835
–
843
32
Johns
MW
1991
A new method for measuring daytime sleepiness: the Epworth sleepiness scale.
Sleep
14
:
540
–
545
33
McNair
DM
, Lorr M Droppleman LF
1971
EITS manual for the profile of mood states
.
San Diego
:
Educational and Industrial Testing Service
34
Barry
MJ
, Fowler Jr FJ O'Leary MP Bruskewitz RC Holtgrewe HL Mebust WK Cockett AT
1992
The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.
J Urol
148
:
1549
–
1557
35
Pocock
SJ
1983
Clinical trials: a practical approach
.
Chichester (West Sussex), New
York
:
Wiley
36
Camargo
CA
1983
Obstructive sleep apnea and testosterone (letter).
N Engl J Med
309
:
314
–
315
37
Bonnet
MH
, Arand DL
1995
We are chronically sleep deprived.
Sleep
18
:
908
–
911
38
Persson
HE
, Svanborg E
1996
Sleep deprivation worsens obstructive sleep apnea. Comparison between diurnal and nocturnal polysomnography.
Chest
109
:
645
–
650
39
Grunstein
RR
, Stenlof K Hedner J Sjostrom L
1995
Impact of obstructive sleep apnea and sleepiness on metabolic and cardiovascular risk factors in the Swedish Obese Subjects (SOS) Study.
Int J Obes Relat Metab Disord
19
:
410
–
418
40
Vgontzas
AN
, Papanicolaou DA Bixler EO Hopper K Lotsikas A Lin HM Kales A Chrousos GP
2000
Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia.
J Clin Endocrinol Metab
85
:
1151
–
1158
41
Brooks
B
, Cistulli PA Borkman M Ross G McGhee S Grunstein RR Sullivan CE Yue DK
1994
Obstructive sleep apnea in obese noninsulin-dependent diabetic patients: effect of continuous positive airway pressure treatment on insulin responsiveness.
J Clin Endocrinol Metab
79
:
1681
–
1685
42
Ip
MS
, Lam B Ng MM Lam WK Tsang KW Lam KS
2002
Obstructive sleep apnea is independently associated with insulin resistance.
Am J Respir Crit Care Med
165
:
670
–
676
43
Punjabi
NM
, Sorkin JD Katzel LI Goldberg AP Schwartz AR Smith PL
2002
Sleep-disordered breathing and insulin resistance in middle-aged and overweight men.
Am J Respir Crit Care Med
165
:
677
–
682
44
Smulders
FT
, Kenemans JL Jonkman LM Kok A
1997
The effects of sleep loss on task performance and the electroencephalogram in young and elderly subjects.
Biol Psychol
45
:
217
–
239
45
Turkington
PM
, Sircar M Allgar V Elliott MW
2001
Relationship between obstructive sleep apnoea, driving simulator performance, and risk of road traffic accidents.
Thorax
56
:
800
–
805
46
Katz
I
, Stradling J Slutsky AS Zamel N Hoffstein V
1990
Do patients with obstructive sleep apnea have thick necks?
Am Rev Respir Dis
141
:
1228
–
1231
47
Shelton
KE
, Woodson H Gay S Suratt PM
1993
Pharyngeal fat in obstructive sleep apnea.
Am Rev Respir Dis
148
:
462
–
466
48
Schwab
RJ
, Gupta KB Gefter WB Metzger LJ Hoffman EA Pack AI
1995
Upper airway and soft tissue anatomy in normal subjects and patients with sleep-disordered breathing. Significance of the lateral pharyngeal walls.
Am J Respir Crit Care Med
152
:
1673
–
1689
49
Bhasin
S
, Woodhouse L Casaburi R Singh AB Bhasin D Berman N Chen X Yarasheski KE Magliano L Dzekov C Dzekov J Bross R Phillips J Sinha-Hikim I Shen R Storer TW
2001
Testosterone dose-response relationships in healthy young men
.
Am J Physiol Endocrinol Metab
281
:
E1172
–
E1181
50
Fogel
RB
, Malhotra A Pillar G Pittman SD Dunaif A White DP
2001
Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome.
J Clin Endocrinol Metab
86
:
1175
–
1180
51
Dexter
DD
, Dovre EJ
1998
Obstructive sleep apnea due to endogenous testosterone production in a woman.
Mayo Clin Proc
73
:
246
–
248
52
Johnson
MW
, Anch AM Remmers JE
1984
Induction of the obstructive sleep apnea syndrome in a woman by exogenous androgen administration.
Am Rev Respir Dis
129
:
1023
–
1025
53
Cistulli
PA
, Grunstein RR Sullivan CE
1994
Effect of testosterone administration on upper airway collapsibility during sleep.
Am J Respir Crit Care Med
149
:
530
–
532
54
White
DP
, Schneider BK Santen RJ McDermott M Pickett CK Zwillich CW Weil JV
1985
Influence of testosterone on ventilation and chemosensitivity in male subjects.
J Appl Physiol
59
:
1452
–
1457
55
Zhou
XS
, Rowley JA Demirovic F Diamond MP Badr MS
2003
Effect of testosterone on the apneic threshold in females during NREM sleep.
J Appl Physiol
94
:
101
–
107
56
Fink
G
, Sumner B Rosie R Wilson H McQueen J
1999
Androgen actions on central serotonin neurotransmission: relevance for mood, mental state and memory.
Behav Brain Res
105
:
53
–
68
57
Bonnet
MH
, Arand DL
1995
24-Hour metabolic rate in insomniacs and matched normal sleepers.
Sleep
18
:
581
–
588
58
Amory
JK
, Chansky HA Chansky KL Camuso MR Hoey CT Anawalt BD Matsumoto AM Bremner WJ
2002
Preoperative supraphysiological testosterone in older men undergoing knee replacement surgery.
J Am Geriatr Soc
50
:
1698
–
1701
59
Bland
JM
, Altman DG
1994
Regression towards the mean.
BMJ
308
:
1499
60
Handelsman
DJ
1998
The safety of androgens: prostate and cardiovascular disease. In: Wang C, ed
.
Male reproductive function. Boston
:
Kluwer Academic Publishers; 227–237.
61
Drinka
PJ
, Jochen AL Cuisinier M Bloom R Rudman I Rudman D
1995
Polycythemia as a complication of testosterone replacement therapy in nursing home men with low testosterone levels.
J Am Geriatr Soc
43
:
899
–
901
62
Rossouw
JE
, Anderson GL Prentice RL LaCroix AZ Kooperberg C Stefanick ML Jackson RD Beresford SA Howard BV Johnson KC Kotchen JM Ockene J
2002
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.
JAMA
288
:
321
–
333
Copyright © 2003 by The Endocrine Society
55,500 Views
156 Citations
Email alerts
Related articles in PubMed
Citing articles via
Will Getting A Testosterone Shot Make You Lose Sleep
Source: https://academic.oup.com/jcem/article/88/8/3605/2845283#:~:text=Short%2Dterm%20administration%20of%20high,%2C%20mental%2C%20or%20metabolic%20function.
